FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
Stock Information for FSD Pharma Inc.
Loading
Please wait while we load your information from QuoteMedia.